Trial
NCT03637764
Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Sanofi
Collaborators
—
Condition
Neoplasm
Intervention
Isatuximab SAR650984
Why stopped
Study was stopped after interim analysis for 4 cohorts (HCC, SCCHN, EOC, and GBM) indicated that the results did not fulfill the preplanned interim analysis criteria to move to Phase 2 stage 2 in all 4 cohorts.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-07-10